Literature DB >> 22020941

MicroRNA-31 regulated by the extracellular regulated kinase is involved in vascular smooth muscle cell growth via large tumor suppressor homolog 2.

Xiaojun Liu1, Yunhui Cheng, Xiuwei Chen, Jian Yang, Ling Xu, Chunxiang Zhang.   

Abstract

Aberrant growth of vascular smooth muscle cells (VSMCs) is a major cellular event in the pathogenesis of many proliferative vascular diseases. Recently, microRNA-31 (miR-31) has been found to play a critical role in cancer cell proliferation. However, the biological role of miR-31 in VSMC growth and the mechanisms involved are currently unknown. In the present study, the expression of rat mature miR-31 (rno-miR-31) was determined in cultured VSMCs and in rat carotid arteries. We identified that rno-miR-31 is an abundant miRNA in VSMCs, and its expression was significantly increased in proliferative VSMCs and in vascular walls with neointimal growth. The up-regulation of rno-miR-31 in proliferative VSMCs was inhibited by the inhibitor of mitogen-activated protein kinase/extracellular regulated kinase (MAPK/ERK). By both gain-of-function and loss-of-function approaches, we demonstrated that rno-miR-31 had a proproliferative effect on VSMCs. We further identified that LATS2 (large tumor suppressor homolog 2) is a downstream target gene product of rno-miR-31 that is involved in rno-miR-31-mediated effect on VSMC proliferation. The LATS2 as a target gene protein of rno-miR-31 is verified in vivo in balloon-injured rat carotid arteries. The results suggest that MAPK/ERK/miR-31/LATS2 may represent a novel signaling pathway in VSMC growth. miR-31 is able to enhance VSMC proliferation via its downstream target gene product, LATS2.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020941      PMCID: PMC3234904          DOI: 10.1074/jbc.M111.261065

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  miR-31 functions as a negative regulator of lymphatic vascular lineage-specific differentiation in vitro and vascular development in vivo.

Authors:  Deena M Leslie Pedrioli; Terhi Karpanen; Vasilios Dabouras; Giorgia Jurisic; Glenn van de Hoek; Jay W Shin; Daniela Marino; Roland E Kälin; Sebastian Leidel; Paolo Cinelli; Stefan Schulte-Merker; André W Brändli; Michael Detmar
Journal:  Mol Cell Biol       Date:  2010-05-17       Impact factor: 4.272

2.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Authors:  Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

3.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

Review 4.  The evolution of gene regulation by transcription factors and microRNAs.

Authors:  Kevin Chen; Nikolaus Rajewsky
Journal:  Nat Rev Genet       Date:  2007-02       Impact factor: 53.242

5.  miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma.

Authors:  Chung-Ji Liu; Meng-Miao Tsai; Pei-Shih Hung; Shou-Yen Kao; Tsung-Yun Liu; Kou-Juey Wu; Shih-Hwa Chiou; Shu-Chun Lin; Kuo-Wei Chang
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

6.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

Authors:  P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

7.  MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.

Authors:  Xi Liu; Lorenzo F Sempere; Haoxu Ouyang; Vincent A Memoli; Angeline S Andrew; Yue Luo; Eugene Demidenko; Murray Korc; Wei Shi; Meir Preis; Konstantin H Dragnev; Hua Li; James Direnzo; Mads Bak; Sarah J Freemantle; Sakari Kauppinen; Ethan Dmitrovsky
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

8.  Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts.

Authors:  N Yabuta; T Fujii; N G Copeland; D J Gilbert; N A Jenkins; H Nishiguchi; Y Endo; S Toji; H Tanaka; Y Nishimune; H Nojima
Journal:  Genomics       Date:  2000-01-15       Impact factor: 5.736

9.  Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer.

Authors:  O Slaby; M Svoboda; P Fabian; T Smerdova; D Knoflickova; M Bednarikova; R Nenutil; R Vyzula
Journal:  Oncology       Date:  2008-01-15       Impact factor: 2.935

10.  Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling.

Authors:  Zain Paroo; Xuecheng Ye; She Chen; Qinghua Liu
Journal:  Cell       Date:  2009-10-02       Impact factor: 41.582

View more
  46 in total

Review 1.  MicroRNA regulation of smooth muscle gene expression and phenotype.

Authors:  Hara Kang; Akiko Hata
Journal:  Curr Opin Hematol       Date:  2012-05       Impact factor: 3.284

2.  Regulation of miRNAs in human skeletal muscle following acute endurance exercise and short-term endurance training.

Authors:  Aaron P Russell; Severine Lamon; Hanneke Boon; Shogo Wada; Isabelle Güller; Erin L Brown; Alexander V Chibalin; Juleen R Zierath; Rod J Snow; Nigel Stepto; Glenn D Wadley; Takayuki Akimoto
Journal:  J Physiol       Date:  2013-06-24       Impact factor: 5.182

Review 3.  Noncoding RNAs in smooth muscle cell homeostasis: implications in phenotypic switch and vascular disorders.

Authors:  N Coll-Bonfill; B de la Cruz-Thea; M V Pisano; M M Musri
Journal:  Pflugers Arch       Date:  2016-04-25       Impact factor: 3.657

Review 4.  The short and long of noncoding sequences in the control of vascular cell phenotypes.

Authors:  Joseph M Miano; Xiaochun Long
Journal:  Cell Mol Life Sci       Date:  2015-05-29       Impact factor: 9.261

Review 5.  MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis.

Authors:  Paola Rinchetti; Mafalda Rizzuti; Irene Faravelli; Stefania Corti
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

Review 6.  Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders.

Authors:  F V Brozovich; C J Nicholson; C V Degen; Yuan Z Gao; M Aggarwal; K G Morgan
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

Review 7.  Function and regulation of microRNA-31 in development and disease.

Authors:  Nadezda A Stepicheva; Jia L Song
Journal:  Mol Reprod Dev       Date:  2016-08-02       Impact factor: 2.609

8.  Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells.

Authors:  Wen Jin; Marpadga A Reddy; Zhuo Chen; Sumanth Putta; Linda Lanting; Mitsuo Kato; Jung Tak Park; Manasa Chandra; Charles Wang; Rajendra K Tangirala; Rama Natarajan
Journal:  J Biol Chem       Date:  2012-03-19       Impact factor: 5.157

9.  Role of MiR-126a-3p in Endothelial Injury in Endotoxic Mice.

Authors:  Maoping Chu; Shanshan Qin; Rongzhou Wu; Xiangyu Zhou; Xiaojun Tang; Shuo Zhang; Qifeng Zhao; Huating Wang; Ying Liu; Xiaohua Han; Jian Xiao; Xiaokun Li; Chunxiang Zhang
Journal:  Crit Care Med       Date:  2016-08       Impact factor: 7.598

10.  NF-κB-responsive miRNA-31-5p elicits endothelial dysfunction associated with preeclampsia via down-regulation of endothelial nitric-oxide synthase.

Authors:  Suji Kim; Kyu-Sun Lee; Seunghwan Choi; Joohwan Kim; Dong-Keon Lee; Minsik Park; Wonjin Park; Tae-Hoon Kim; Jong Yun Hwang; Moo-Ho Won; Hansoo Lee; Sungwoo Ryoo; Kwon-Soo Ha; Young-Guen Kwon; Young-Myeong Kim
Journal:  J Biol Chem       Date:  2018-10-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.